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Abstract
ATP-binding cassette (ABC) superfamily proteins have divergent functions and can be classified as transporters, channels,
and receptors, although their predicted secondary structures are very much alike. Prominent members include the
sulfonylurea receptor (SUR1) and the multidrug transporter (MDR1). SUR1 is a subunit of the pancreatic L-cell KATP
channel and plays a key role in the regulation of glucose-induced insulin secretion. SUR1 binds ATP at NBF1, and ADP at
NBF2 and the two NBFs work cooperatively. The pore-forming subunit of the pancreatic L-cell KATP channel, Kir6.2, is a
member of the inwardly rectifying K channel family, and also binds ATP. In this article, we present a model in which the
activity of the KATP channel is determined by the balance of the action of ADP, which activates the channel through SUR1,
and the action of ATP, which stabilizes the long closed state by binding to Kir6.2. The concentration of ATP could also
affect the channel activity through binding to NBF1 of SUR1. MDR1, on the other hand, is an ATP-dependent efflux pump
which extrudes cytotoxic drugs from cells before they can reach their intracellular targets, and in this way confers multidrug
resistance to cancer cells. Both NBFs of MDR1 can hydrolyze nucleotides, and their ATPase activity is necessary for drug
transport. The interaction of SUR1 with nucleotides is quite different from that of MDR1. Variations in the interactions with
nucleotides of ABC proteins may account for the differences in their functions. ß 1999 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Every cell is surrounded by a plasma membrane,
which separates it from the outside world. To take
up essential nutrients and to excrete metabolic waste
products and environmental toxic substances, cells
have developed ways of transferring materials across
their membranes. To regulate intracellular ion con-
centrations, they have developed ways of transferring
ions across their membranes. These transfer activities
are handled by special membrane proteins, transport-
ers and channels. Cells also have a family of receptor
membrane proteins for transmitting signals from out-
side to inside for intercellular communication and for
responding to the external environment.
The functions of these three types of membrane
proteins, transporters, channels, and receptors, are
quite di¡erent (Fig. 1). Transporters bind tightly to
their speci¢c substrates and transfer the bound sub-
strates across the membrane coupled with conforma-
tional changes. Channel proteins, on the other hand,
do not bind tightly to the transport ions. They
undergo conformational changes to enter the con-
ducting state, but ion transport is not coupled to
these changes. Receptors transmit the information
of ligand binding, but do not necessarily transport
the ligands themselves. The most striking and inter-
esting feature of the ATP-binding cassette (ABC)
protein superfamily is that its members exhibit three
di¡erent types of functions despite being very much
alike in their predicted secondary structures.
The images of Fig. 2 represent transporters, chan-
nels, and receptors to show how these three groups
of membrane proteins di¡er in their functions.
MDR1/P-glycoprotein is an active transporter, in
which ATP hydrolysis provides the free energy nec-
essary to continue extruding chemotherapeutic drugs
from cells like a water pump. Cystic ¢brosis trans-
membrane conductance regulator (CFTR), a chloride
channel, is like a pipe with a gate. ATP hydrolysis
may allow the gate to open or close, but is not
coupled to ion £ow. Sulfonylurea receptor (SUR1)
may function like a switch which regulates the K
channel. We have previously studied how ATP is
used by functionally di¡erent ABC proteins SUR1
and MDR1. In this article, we describe working
models of SUR1 and MDR1, with a brief description
of techniques used to analyze them, to clarify their
similarities and di¡erences.
2. Regulation of L-cell KATP channels by adenine
nucleotides and pharmacological agents
ATP-sensitive potassium (KATP) channels play
many important roles in various tissues by linking
the cell metabolic state to the membrane potential
[1^3]. The KATP channels in pancreatic L-cells, for
example, are critical in the regulation of glucose-in-
duced insulin secretion [4^8]. Electrophysiological
studies have provided clues to the complex control
of KATP channels by ATP and ADP. In the current
model (Fig. 3) of glucose-induced insulin secretion,
glucose is transported through the glucose transport-
er and the subsequent metabolism of glucose in-Fig. 1. Three types of functional membrane proteins.
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creases ATP and concomitantly decreases ADP in
pancreatic L-cells. The increase in the ATP/ADP ra-
tio closes the KATP channels, which depolarizes the
L-cell membrane, leads to the opening of voltage-de-
pendent Ca2 channels, and allows a Ca2 in£ux into
the L-cells. The resultant rise in intracellular Ca2
concentration triggers insulin release. The pancreatic
L-cell KATP channels are also regulated by important
therapeutic pharmacological agents, such as sulfonyl-
ureas and K-channel openers. Sulfonylureas, widely
used in the treatment of non-insulin dependent dia-
betes mellitus, stimulate insulin secretion by closing
the KATP channels, while K-channel openers inhibit
insulin secretion by opening the KATP channels [9].
The pancreatic L-cell KATP channel is a complex of
two subunits [10,11]: SUR1 subunits of the ABC
superfamily with two nucleotide binding folds
(NBF1 and NBF2) and Kir6.2 subunits, of the in-
wardly rectifying K channel family. SUR1 and
Kir6.2 coassemble in a 4:4 stoichiometry to form
KATP channels [12^14], and this fully assembled oc-
tameric stoichiometry is necessary for proper KATP
channel gating [15]. Because mutation in either of the
NBFs of SUR1 abolish MgADP-induced channel
activation [14,16,17], SUR1 is thought to mediate
the stimulatory e¡ect of MgADP. SUR1 is also the
primary target for the pharmacological agents, sulfo-
nylureas, such as glibenclamide and K-channel
openers, such as diazoxide [18,19]. The primary site
of ATP inhibition of KATP channel activity appears
to be in Kir6.2 [20,21]. However, the regulation of
the L-cell KATP channels by adenine nucleotides and
pharmacological agents is quite complex, even para-
doxical. First, when membrane patches are excised
into a nucleotide-free solution, the L-cell KATP chan-
nels can be observed. However, the current magni-
tude of the L-cell KATP channels slowly declines (run-
down) after patch excision. This ‘run-down’ can be
restored following exposure to MgATP [22],
although ATP inhibits the L-cell KATP channels.
MgATP actually activates KATP channels containing
a mutation in the Kir6.2 subunit that impairs ATP
inhibition (R50G) [23]. Second, although MgADP
stimulates KATP channels, ADP shows inhibitory ef-
fects at high concentrations [24,25]. Third, although
Fig. 2. Drawings representing the three types of ABC proteins.
Fig. 3. A model for glucose-induced insulin secretion via the
pancreatic L-cell KATP channel. GLUT2, glucose transporter 2;
VDCC, voltage-dependent calcium channel.
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the interaction of sulfonylureas with SUR1 abolishes
the stimulatory e¡ect of MgADP on KATP channels
[20], the sensitivity of the KATP channel to sulfonyl-
ureas increases more in the presence of MgADP than
in its absence [26^28].
3. Interaction of SUR1 with adenine nucleotides
SUR1 was transiently expressed in Cos-7 cells and
examined to see if it could be photolabeled with 8-
azido-[K-32P]ATP. Surprisingly, SUR1 was e⁄ciently
photolabeled even in the absence of Mg2 or vana-
date [29]. This feature of ATP binding of SUR1 was
quite di¡erent from that of MDR1 and MRP [30,31],
because both vanadate and Mg2 were required for
the photoa⁄nity labeling of MDR1 and MRP. Bind-
ing of 8-azido-[K-32P]ATP or 8-azido-[Q-32P]ATP to
SUR1 was apparently saturated at around 10 WM
and then increased with increasing concentrations
of 8-azido ATP. These results suggest that the bound
nucleotide in SUR1 is ATP, and that SUR1 may
have two ATP binding sites, one of high a⁄nity
and the other of low a⁄nity. Analysis of ATP bind-
ing of mutants suggested that NBF1 is the high-af-
¢nity ATP binding site. 8-Azido-ATP was found to
continue to bind to SUR1 stably in the presence of
Mg2 for more than 15 min at 0‡C [32]. We expected
that this strong and stable ATP binding to NBF1
might make it possible to investigate the interaction
between the two NBFs of SUR1.
Two procedures, a ‘preincubation procedure’ and
a ‘postincubation procedure’ were used, to analyze
the interactions of SUR1 with adenine nucleotides
(Fig. 4). First, the membrane proteins were preincu-
bated with ADP at 0‡C, and then allowed to react
with 8-azido-[K-32P]ATP in the presence of ADP
(‘preincubation procedure’) [29]. With the preincuba-
tion procedure, ADP, in the presence of Mg2,
strongly antagonized 8-azido-ATP binding. This in-
hibitory e¡ect of MgADP was reduced by mutations
in NBF2. ADP weakly antagonized 8-azido-ATP
binding in the absence of Mg2. MgADP bound at
NBF2 was assumed to facilitate MgADP binding at
NBF1, thereby preventing 8-azido-ATP binding to
NBF1 and two NBFs of SUR1 were suggested to
work cooperatively. To further analyze this cooper-
ative interaction between the two NBFs of SUR1, we
used the ‘postincubation procedure’ (Fig. 4) [32]. In
this procedure, membrane proteins were ¢rst incu-
bated with 8-azido-[K-32P]ATP at 37‡C for 3 min,
and free ligand was removed. Next, the membrane
proteins were postincubated for 15 min in the pres-
ence or absence of unlabeled nucleotide, and irradi-
ated with UV. With this procedure, we found that
MgADP and MgATP stabilize prebound 8-azido-
ATP binding, but it dissociates gradually at 37‡C
in the presence of Mg2 alone. The e¡ects of
MgADP and MgATP on the stabilization of pre-
bound 8-azido-ATP binding to SUR1 were concen-
tration-dependent from 10 WM, and maximal e¡ects
were at 0.5 mM for both. The slowly hydrolysable
ATP analog, ATP-QS, had no greater stabilizing ef-
fect than Mg2 alone. Mutations in the Walker A
and B motifs of NBF2 had almost no e¡ect on the
¢rst 8-azido-ATP binding, but abolished the stabiliz-
ing e¡ects of MgADP on 8-azido-ATP binding.
These results suggest that MgADP, either by direct
binding to NBF2 or hydrolysis of bound MgATP,
very likely induces a conformational change at
NBF2 which transduces another conformational
change in NBF1 to stabilize ATP binding at NBF1.
When SUR1, which binds with 8-azido-ATP at
NBF1, was incubated with sulfonylurea glibencla-
mide in the presence of 0.5 mM MgADP or MgATP,
photoa⁄nity labeling was reduced in a concentra-
tion-dependent manner [32], suggesting that gliben-
clamide modulates the cooperative interaction of the
two NBFs of SUR1.
Fig. 4. Schematic diagrams of the reaction of SUR1 with nu-
cleotides. (A) Preincubation procedure [29]. (B) Postincubation
procedure [32].
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4. Cooperative ATP binding/hydrolysis cycle model of
SUR1
Based on these biochemical results, a model of the
cooperative ATP binding/hydrolysis cycle of SUR1
was proposed (Fig. 5) [32]. In this model, SUR1
changes its conformation by binding ATP in NBF1
and ADP in NBF2. This state 1 is proposed to be the
active form of SUR1. When the intracellular ADP
concentration decreases, ADP dissociates from
NBF2 (state 2). ADP interacts with NBF2 either
by direct binding or hydrolysis of bound ATP (state
3). States 1 and 2 are states of equilibrium, and most
of the SUR1 subunits will be in state 1 at high ADP
concentration and in state 2 at low ADP concentra-
tions. ADP dissociation from NBF2 leads to insta-
bility of ATP binding at NBF1, allowing the release
of ATP (state 4). This dissociation of ATP from
NBF1 may be involved in channel inactivation.
Under physiological conditions, the intracellular
ATP concentration is high enough, and ATP bound
to NBF2 is readily hydrolyzed to ADP. Conse-
quently, SUR1 is in either state 1, 2, or 3. According
to this model, ATP binding at NBF1 is required for
the active state of SUR1, and the intracellular con-
centration of ADP is the primary factor determining
the activity of SUR1. Importantly, glibenclamide
may convert an active state of SUR1 directly to the
inactive state by dissociating ATP from NBF1. Gli-
benclamide causes release of ATP from NBF1 in
cooperation with ADP at NBF2.
5. Working model of the function of the pancreatic
L-cell KATP channel
The pore-forming subunit of pancreatic L-cell
KATP channel, Kir6.2, is a member of the inwardly
rectifying K channel family (Fig. 6) [10,11]. Unlike
most other Kir channels, expression of Kir6.2 alone
does not produce functional channel activity; it re-
quires coexpression with SUR1. Recently, it has been
clearly shown that SUR1 and Kir6.2 contain a novel
motif for endoplasmic reticulum retention/retrieval,
and that this motif is required at multiple stages of
the KATP channel assembly to restrict surface expres-
sion to fully assembled and correctly regulated octa-
meric channels [15].
An isoform of Kir6.2, in which the last 26 amino
acids including the motif for endoplasmic reticulum
retention/retrieval have been removed (Kir6.2vC26),
is capable of expressing functional K channel activ-
ity in the absence of SUR1. Kir6.2vC26 retains sen-
sitivity to inhibition by ATP and mutations in this
subunit can signi¢cantly reduce the inhibitory e¡ect
of ATP [20,33]. Recently, the pore-forming subunit
Kir6.2 was demonstrated to be directly labeled by 8-
azido-[Q-32P]ATP [34], although Kir6.2 has much
lower a⁄nity for 8-azido-ATP than SUR1. Muta-
tions in the NH2-terminus (R50G) and the COOH-
Fig. 6. Schematic showing of Kir6.2. Mutations of arginine-50
and lysine-185 reduce the inhibitory e¡ect of ATP upon Kir6.2
channel activity and ATP binding [34].
Fig. 5. Model for nucleotide activation of the KATP channel by
SUR1 subunit. Nucleotide binding folds (NBFs) in the inactive
state are depicted as circles, those with bound nucleotide and
altered conformation as diamonds. State 1 is the ‘active state’
in which SUR1 potentiates channel activity. States 2 and 3 are
transient, and states 4 and 5 are ‘inactive states’ in which
SUR1 inhibits channel activity. The straight arrows indicate
binding or unbinding reactions and the wavy arrows indicate a
hydrolytic reaction. (Modi¢ed from [32].)
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terminus (K185Q) reduced photoa⁄nity labeling of
Kir6.2 by more than 50% [34]. These mutations have
been shown to reduce the inhibitory e¡ect of ATP
upon Kir6.2 channel activity [33]. These results dem-
onstrate that ATP binds directly to Kir6.2 and that
both the -NH2 and -COOH terminal intracellular
domains may in£uence ATP-binding.
Taking these results into consideration, we pro-
pose a working model for the function of the KATP
channel (Fig. 7). When the intracellular ADP con-
centration is high enough, SUR1 cooperatively binds
ATP in NBF1 and ADP in NBF2, and activates
Kir6.2 to open K channel. After meal consumption,
the plasma glucose concentration rises. The increase
in glucose metabolism raises the cellular ATP con-
centration and concomitantly lowers the cellular
ADP concentration. The decrease in cellular ADP
concentration causes dissociation of ADP from
NBF2 of SUR1. ATP may bind to NBF2 after
ADP dissociation because of the cellular high ATP
concentration, but ATP bound to NBF2 would be
readily hydrolyzed to ADP. Then ADP would disso-
ciate from NBF2. ADP dissociation from NBF2
leads to instability of ATP binding at NBF1, allow-
ing the release of ATP. As a result, SUR1 would not
remain in the active state, when the cellular ADP
concentration is low. With the rise in the cellular
ATP concentration, Kir6.2 would remain longer in
the ATP binding form. ATP binding to Kir6.2 is
speculated to be involved in stabilization of the
long closed state of KATP channel [33]. Therefore,
we assume that the activity of the pancreatic L-cell
KATP channel is determined by the balance of the
action of ADP, which activates the channel through
SUR1, and the action of ATP, which stabilizes the
long closed state by binding to Kir6.2. The concen-
tration of ATP could also a¡ect the channel activity
by binding to NBF1 of SUR1. SUR1 and Kir6.2
coassemble in a 4:4 stoichiometry to form KATP
channels [12^14], and this fully assembled octameric
stoichiometry is necessary for proper KATP channel
gating [15]. Namely, there are four high-a⁄nity ATP
binding sites (NBF1), four MgADP binding sites
(NBF2), and four low-a⁄nity ATP binding sites
(Kir6.2) in a functional KATP channel. Although it
remains an open question how many ATPs and
ADPs are necessary for binding to open and close
the KATP channel, we assume that this octameric
stoichiometry ensures ¢ne-tuning of the KATP chan-
nel gating regulated by changes in cellular ATP and
ADP concentrations.
6. Interaction of MDR1 with ATP
MDR1 is an ATP-dependent e¥ux pump that ex-
trudes cytotoxic drugs from cells before the drugs
reach their intracellular targets, and in this way con-
fers multidrug resistance to cancer cells [35^37]. It
has been suggested that both NBFs of MDR1 can
hydrolyze nucleotides, and their ATPase activity is
necessary for drug transport [38^40]. Senior et al.
have proposed that two NBFs are equivalent in the
functioning of MDR1 [41]. Indeed, mutation of the
Fig. 7. A working model of the function of the pancreatic
L-cell KATP channel. When intracellular ATP concentration is
low and ADP concentration is high (low glucose), SUR1 coop-
eratively binds ATP in NBF1 and ADP in NBF2, and activates
Kir6.2 to open K channel. When intracellular ATP concentra-
tion is high and ADP concentration is low (high glucose), ADP
dissociates from NBF2. ATP binds to NBF2 after ADP dissoci-
ation because of the cellular high ATP concentration, but ATP
bound to NBF2 is readily hydrolyzed to ADP. Next, ADP be-
comes dissociated from NBF2, resulting in instability of the
ATP binding at NBF1 and allowing ATP release. Thus, SUR1
does not remain in the active state. ATP binding to Kir6.2 sta-
bilizes the long closed state of the KATP channel. The activity
of the pancreatic L-cell KATP channel is determined by the bal-
ance ADP action, which activates the channel through SUR1,
and ATP action, which stabilizes the long closed state by bind-
ing to Kir6.2. The concentration of ATP may also a¡ect the
channel activity through the binding to NBF1 of SUR1.
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Walker A lysine residue of either NBF abolishes the
ATPase activity of MDR1 and its ability to confer
multidrug resistance [42^44]. The covalent modi¢ca-
tion of the cysteine residue in the Walker A motif of
either NBF has also been shown to be su⁄cient to
inactivate the ATPase activity of MDR1 [45^48].
However, some non-equivalent features between the
two NBFs have been reported [48].
8-Azido-ATP binding with the wild-type MDR1
was inhibited by 100 WM NEM, while 8-azido-ATP
binding with the C431A/C1074A mutant form was
not, suggesting that the cysteines of Walker A motifs
in both NBFs are responsible for the e¡ects of NEM
on ATP binding. 8-Azido-ATP binding of the C431A
mutant form appeared not to be a¡ected by treat-
ment with 100 WM NEM. However, ATP-binding to
the C1074A mutant form was signi¢cantly reduced
by the same treatment, similar to the wild-type
MDR1. These results suggest that NEM modi¢ca-
tion of NBF1 is responsible for the NEM inhibition
of ATP binding in the wild-type protein. NEM mod-
i¢cation of NBF1 may have an allosteric e¡ect on
ATP binding at NBF2, although that of NBF2 does
not a¡ect further ATP binding at NBF1. Alterna-
tively, NBF1 might be the high-a⁄nity ATP binding
site in the wild-type MDR1. The e¡ect of mutation
of the Walker A lysine in one NBF was also reported
to not be equivalent to that in the other NBF of
MDR1 [48].
7. Similarities and di¡erences in catalytic cycles of
ABC proteins
Cooperative interaction of the two NBFs of ABC
proteins has been shown for MDR1 [42^48], SUR1
[29,32], and CFTR [49,50]. In MDR1, if one NBF is
non-functional, no ATP hydrolysis occurs even if the
other functional NBF contains a bound nucleotide
[48]. It is likely that a conformation induced by
ATP binding at a regulatory NBF is necessary for
ATP hydrolysis at a catalytic NBF. In the alternating
catalytic sites cycle model proposed by Senior et al.
[41], the two NBFs appear to be functionally equiv-
alent, to alternate in catalysis, and one substrate
may be transported by hydrolysis of one ATP. How-
ever, because the two NBFs are not necessarily
equivalent as described above, the possibility remains
that one substrate is transported by hydrolysis of two
ATPs.
In CFTR, both of the NBFs appear to hydrolyze
ATP and to alternate in catalysis [49,50], as those of
MDR1. Cooperativity between the two NBFs is in-
duced by phosphorylation of the regulatory domain
by protein kinase A, which is also necessary for
channel opening [50]. However, the roles of the two
NBFs are predicted to be non-equivalent: NBF1 is
involved in channel opening while NBF2 is involved
in channel closing [49,50]. Therefore, one complete
cycle of opening and closing of a single CFTR chan-
nel requires hydrolysis of two ATP molecules, one at
each NBF. The catalytic cycle of CFTR appears to
be very similar to that of MDR1. However, ATP
hydrolysis would not provide the energy necessary
for conformational changes of CFTR to transport
ions. The tight binding of ATP is predicted to stabi-
lize the channel’s open or closed state, until that
nucleotide is hydrolyzed, similar to the tight binding
of GTP stabilizing the active conformation of a G-
protein [51].
In SUR1, the roles of the two NBFs are predicted
to be non-equivalent: SUR1 binds ATP strongly at
NBF1 and MgADP at NBF2. MgADP interacts with
NBF2, either by direct binding or hydrolysis of
bound MgATP at NBF2. Similar to CFTR, cooper-
ative nucleotide binding to NBFs would stabilize the
active state of SUR1. Interestingly, the predicted ac-
tive state of SUR1 binds ATP at NBF1 and ADP at
NBF2, although, in CFTR, ADP binds at NBF1 and
ATP binds at NBF2 [49,50]. We assume that NBF2
of SUR1 hydrolyzes ATP [32] (Matsuo, M. et al.,
submitted). Because mutations in NBF1 abolish
channel activation by adenine nucleotides
[14,16,17], NBF1 is also assumed to have ATPase
activity [8]. It has also been reported that binding
of potassium channel openers to SURs requires a
conformational change induced by ATP hydrolysis
in both NBFs [52]. However, we have not been
able to obtain any data suggesting ATP hydrolysis
at NBF1 under the conditions examined (Matsuo,
M. et al., submitted). Because the interaction of
SUR1 with adenine nucleotides is quite di¡erent
from MDR1, we assume that SUR1 is not a trans-
porter but a switch, like a G-protein, which regulates
the Kir6.2 K channel. Finally, we would like to
underline the unique feature of SUR1 functioning
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not only as a switch itself, but also monitoring
changes in cellular nucleotide concentrations.
In conclusion, although the predicted secondary
structures of the ABC superfamily proteins are very
much alike, they diverge according to function into
transporters, channels, and receptors. The interaction
of SUR1 with nucleotides is quite di¡erent from that
of MDR1. Variations in the interactions with nucleo-
tides of ABC proteins may account for the di¡eren-
ces in their functions.
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